Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII

Haemophilia

Volumn 15, Issue 6, 2009, Pages 1237-1242

  Rea, C ^a   Dunkerley, A ^a   Sorensen B ^a   Rangarajan, S ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

B domain deleted factor VIII; Clinical outcome; Coagulation factor consumption; Full length factor VIII; Pharmacokinetics

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 8;

ARTICLE; BLEEDING; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; CHILD; CHILD, PRESCHOOL; CROSS-OVER STUDIES; FACTOR VIII; HALF-LIFE; HEMOPHILIA A; HEMORRHAGE; HUMANS; MALE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 70449570710     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02071.x     Document Type: Article

References (15)

1. Lusher JM, Lee CA, Kessler CM, Bedrosian CL. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia 2003, 9:38-49.
2. Courter SG, Bedrosian CL. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients. Semin Hematol 2001, 38:52-9.
3. Gruppo RA, Brown D, Wilkes MM, Navickis RJ. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis - a meta-analysis. Haemophilia 2003, 9:251-60.
4. Keeling D. Switching between full-length and B-domain-deleted factor VIII and the risk of inhibitors. Haemophilia 2006, 12:690-1.
5. Roussel-Robert V, Torchet MF, Legrand F, Rothschild C, Stieltjes N. Factor VIII inhibitors development following introduction of B-domain-deleted recombinant factor VIII in four hemophilia A previously treated patients. J Thromb Haemost 2003, 1:2450-1.
6. Ingerslev J, Jankowski MA, Weston SB, Charles LA. Collaborative field study on the utility of a BDD factor VIII concentrate standard in the estimation of BDDr Factor VIII:C activity in hemophilic plasma using one-stage clotting assays. J Thromb Haemost 2004, 2:623-8.
7. Di PJ, Smith MP, Klamroth R. ReFacto and Advate: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A. Haemophilia 2007, 13:124-30.
8. Smith MP, Giangrande P, Pollman H, Littlewood R, Kollmer C, Feingold J. A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A. Haemophilia 2005, 11:444-51.
9. Ingerslev J, Poulsen LH, Sorensen B. Potential role of the dynamic properties of whole blood coagulation in assessment of dosage requirements in haemophilia. Haemophilia 2003, 9:348-52.
10. Brown SA, Yee TT, Griffioen A, Lee CA. Comparative study of full-length and B-domain deleted factor VIII concentrates. Haemophilia 2003, 9:745-50.
11. Lee ML, Morfini M. Controversial use of meta-analysis for factor VIII pharmacokinetic data. Haemophilia 2003, 9:746-7.
12. van der Bom JG, Fischer K, van den Berg HM. Meta-analysis on the effectiveness of B-domain deleted factor VIII for prophylaxis. Haemophilia 2003, 9:744-50.
13. Gringeri A, Tagliaferri A, Tagariello G, Morfini M, Santagostino E, Mannucci P. Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII. Br J Haematol 2004, 126:398-404.
14. Jankowski MA, Patel H, Rouse JC, Marzilli LA, Weston SB, Sharpe PJ. Defining 'full-length' recombinant factor VIII: a comparative structural analysis. Haemophilia 2007, 13:30-7.
15. Messori A, Longo G, Morfini M. Multi-variate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs. Eur J Clin Pharmacol 1988, 35:663-8.